source
- Israeli biotech's inhaled exosome therapy cuts respiratory failure and mortality in ARDS phase 2b trialNano24, an Israeli biotech company, tested its inhaled exosome product EXO‑CD24 in a mid‑stage study involving 90 patients with acute respiratory distress syndrome. The trial compared the therapy,…
- Pathos AI partners with BMS and Tempus to use AI for Alzheimer’s drug developmentPathos AI announced two collaborations aimed at accelerating drug development for neurological disorders, including Alzheimer’s disease. The agreement with Bristol Myers Squibb gives the pharma co…